Promising Top-line Results For Long COVID Treatment Announced By This Medical Research Company

AIM ImmunoTech's Ampligen® Shows Promise in Treating Post-COVID Conditions: A Significant Breakthrough?

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, I may earn a commission.

In a significant development that holds promise for millions affected by the long-term effects of COVID-19, AIM ImmunoTech Inc. (NYSE American: AIM) recently announced positive topline results from its Phase 2 study evaluating…